- You are viewing a Navigating Care library resource.
- Go to Library
Treatment of Recurrent Metastatic Squamous Neck Cancer with Occult Primary
For information about the treatments listed below, see the Treatment Option Overview section.
Treatment of metastatic squamous neck cancer with occult primary that recurs (comes back) after treatment is usually within a clinical trial.
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
This information is not intended to replace the advice of a doctor.
Navigating Care disclaims any liability for the decisions you make based on this information.
This information was sourced and adapted from Adapted from the National Cancer Institute's
Physician Data Query (PDQ®) Cancer Information Summaries on
www.cancer.gov.
This information updated
November 1, 2024.
Learn more:
- General Information About Metastatic Squamous Neck Cancer with Occult Primary
- Stages of Metastatic Squamous Neck Cancer with Occult Primary
- Treatment Option Overview
- Treatment of Untreated Metastatic Squamous Neck Cancer with Occult Primary
- Treatment of Recurrent Metastatic Squamous Neck Cancer with Occult Primary
- To Learn More About Metastatic Squamous Neck Cancer with Occult Primary
Related Articles
- General Information About Metastatic Squamous Neck Cancer with Occult Primary
- Stages of Metastatic Squamous Neck Cancer with Occult Primary
- Treatment Option Overview
- Treatment of Untreated Metastatic Squamous Neck Cancer with Occult Primary
- Treatment of Recurrent Metastatic Squamous Neck Cancer with Occult Primary
- To Learn More About Metastatic Squamous Neck Cancer with Occult Primary
More Resources
See Expert Resources
The Navigating Care Library includes articles about cancer, chemotherapy regimens and drugs from the
the National Cancer Institute and other experts.
